369 related articles for article (PubMed ID: 27621445)
21. Combinatorial treatment for spinal muscular atrophy: An Editorial for 'Combined treatment with the histone deacetylase inhibitor LBH589 and a splice-switch antisense oligonucleotide enhances SMN2 splicing and SMN expression in Spinal Muscular Atrophy cells' on page 264.
Poletti A; Fischbeck KH
J Neurochem; 2020 Apr; 153(2):146-149. PubMed ID: 32056234
[TBL] [Abstract][Full Text] [Related]
22. Myostatin inhibition in combination with antisense oligonucleotide therapy improves outcomes in spinal muscular atrophy.
Zhou H; Meng J; Malerba A; Catapano F; Sintusek P; Jarmin S; Feng L; Lu-Nguyen N; Sun L; Mariot V; Dumonceaux J; Morgan JE; Gissen P; Dickson G; Muntoni F
J Cachexia Sarcopenia Muscle; 2020 Jun; 11(3):768-782. PubMed ID: 32031328
[TBL] [Abstract][Full Text] [Related]
23. New and Developing Therapies in Spinal Muscular Atrophy: From Genotype to Phenotype to Treatment and Where Do We Stand?
Chen TH
Int J Mol Sci; 2020 May; 21(9):. PubMed ID: 32392694
[TBL] [Abstract][Full Text] [Related]
24. The oral splicing modifier RG7800 increases full length survival of motor neuron 2 mRNA and survival of motor neuron protein: Results from trials in healthy adults and patients with spinal muscular atrophy.
Kletzl H; Marquet A; Günther A; Tang W; Heuberger J; Groeneveld GJ; Birkhoff W; Mercuri E; Lochmüller H; Wood C; Fischer D; Gerlach I; Heinig K; Bugawan T; Dziadek S; Kinch R; Czech C; Khwaja O
Neuromuscul Disord; 2019 Jan; 29(1):21-29. PubMed ID: 30553700
[TBL] [Abstract][Full Text] [Related]
25. Systemic and ICV Injections of Antisense Oligos into SMA Mice and Evaluation.
Aslesh T; Maruyama R; Yokota T
Methods Mol Biol; 2018; 1828():455-465. PubMed ID: 30171559
[TBL] [Abstract][Full Text] [Related]
26. The Power of Human Protective Modifiers: PLS3 and CORO1C Unravel Impaired Endocytosis in Spinal Muscular Atrophy and Rescue SMA Phenotype.
Hosseinibarkooie S; Peters M; Torres-Benito L; Rastetter RH; Hupperich K; Hoffmann A; Mendoza-Ferreira N; Kaczmarek A; Janzen E; Milbradt J; Lamkemeyer T; Rigo F; Bennett CF; Guschlbauer C; Büschges A; Hammerschmidt M; Riessland M; Kye MJ; Clemen CS; Wirth B
Am J Hum Genet; 2016 Sep; 99(3):647-665. PubMed ID: 27499521
[TBL] [Abstract][Full Text] [Related]
27. Nusinersen: A Review in 5q Spinal Muscular Atrophy.
Hoy SM
CNS Drugs; 2021 Dec; 35(12):1317-1328. PubMed ID: 34850360
[TBL] [Abstract][Full Text] [Related]
28. CHP1 reduction ameliorates spinal muscular atrophy pathology by restoring calcineurin activity and endocytosis.
Janzen E; Mendoza-Ferreira N; Hosseinibarkooie S; Schneider S; Hupperich K; Tschanz T; Grysko V; Riessland M; Hammerschmidt M; Rigo F; Bennett CF; Kye MJ; Torres-Benito L; Wirth B
Brain; 2018 Aug; 141(8):2343-2361. PubMed ID: 29961886
[TBL] [Abstract][Full Text] [Related]
29. Nusinersen: antisense oligonucleotide to increase SMN protein production in spinal muscular atrophy.
Paton DM
Drugs Today (Barc); 2017 Jun; 53(6):327-337. PubMed ID: 28799578
[TBL] [Abstract][Full Text] [Related]
30. The Antisense Transcript SMN-AS1 Regulates SMN Expression and Is a Novel Therapeutic Target for Spinal Muscular Atrophy.
d'Ydewalle C; Ramos DM; Pyles NJ; Ng SY; Gorz M; Pilato CM; Ling K; Kong L; Ward AJ; Rubin LL; Rigo F; Bennett CF; Sumner CJ
Neuron; 2017 Jan; 93(1):66-79. PubMed ID: 28017471
[TBL] [Abstract][Full Text] [Related]
31. In Vitro Evaluation of Antisense-Mediated Exon Inclusion for Spinal Muscular Atrophy.
Touznik A; Maruyama R; Yokota T
Methods Mol Biol; 2018; 1828():439-454. PubMed ID: 30171558
[TBL] [Abstract][Full Text] [Related]
32. Development and characterization of an SMN2-based intermediate mouse model of Spinal Muscular Atrophy.
Cobb MS; Rose FF; Rindt H; Glascock JJ; Shababi M; Miller MR; Osman EY; Yen PF; Garcia ML; Martin BR; Wetz MJ; Mazzasette C; Feng Z; Ko CP; Lorson CL
Hum Mol Genet; 2013 May; 22(9):1843-55. PubMed ID: 23390132
[TBL] [Abstract][Full Text] [Related]
33. DG9-conjugated morpholino rescues phenotype in SMA mice by reaching the CNS via a subcutaneous administration.
Aslesh T; Erkut E; Ren J; Lim KRQ; Woo S; Hatlevig S; Moulton HM; Gosgnach S; Greer J; Maruyama R; Yokota T
JCI Insight; 2023 Mar; 8(5):. PubMed ID: 36719755
[TBL] [Abstract][Full Text] [Related]
34. NCALD Antisense Oligonucleotide Therapy in Addition to Nusinersen further Ameliorates Spinal Muscular Atrophy in Mice.
Torres-Benito L; Schneider S; Rombo R; Ling KK; Grysko V; Upadhyay A; Kononenko NL; Rigo F; Bennett CF; Wirth B
Am J Hum Genet; 2019 Jul; 105(1):221-230. PubMed ID: 31230718
[TBL] [Abstract][Full Text] [Related]
35. Rescue of gene-expression changes in an induced mouse model of spinal muscular atrophy by an antisense oligonucleotide that promotes inclusion of SMN2 exon 7.
Staropoli JF; Li H; Chun SJ; Allaire N; Cullen P; Thai A; Fleet CM; Hua Y; Bennett CF; Krainer AR; Kerr D; McCampbell A; Rigo F; Carulli JP
Genomics; 2015 Apr; 105(4):220-8. PubMed ID: 25645699
[TBL] [Abstract][Full Text] [Related]
36. Amphiphilic lipopeptide significantly enhances uptake of charge-neutral splice switching morpholino oligonucleotide in spinal muscular atrophy patient-derived fibroblasts.
Tajik-Ahmadabad B; Polyzos A; Separovic F; Shabanpoor F
Int J Pharm; 2017 Oct; 532(1):21-28. PubMed ID: 28864392
[TBL] [Abstract][Full Text] [Related]
37. A SMN2 Splicing Modifier Rescues the Disease Phenotypes in an In Vitro Human Spinal Muscular Atrophy Model.
Son YS; Choi K; Lee H; Kwon O; Jung KB; Cho S; Baek J; Son B; Kang SM; Kang M; Yoon J; Shen H; Lee S; Oh JH; Lee HA; Lee MO; Cho HS; Jung CR; Kim J; Cho S; Son MY
Stem Cells Dev; 2019 Apr; 28(7):438-453. PubMed ID: 30667343
[TBL] [Abstract][Full Text] [Related]
38. Nusinersen: A Review in 5q Spinal Muscular Atrophy.
Hoy SM
CNS Drugs; 2018 Jul; 32(7):689-696. PubMed ID: 30027400
[TBL] [Abstract][Full Text] [Related]
39. Improvement of spinal muscular atrophy via correction of the SMN2 splicing defect by Brucea javanica (L.) Merr. extract and Bruceine D.
Baek J; Jeong H; Ham Y; Jo YH; Choi M; Kang M; Son B; Choi S; Ryu HW; Kim J; Shen H; Sydara K; Lee SW; Kim SY; Han SB; Oh SR; Cho S
Phytomedicine; 2019 Dec; 65():153089. PubMed ID: 31563042
[TBL] [Abstract][Full Text] [Related]
40. Investigation of New Morpholino Oligomers to Increase Survival Motor Neuron Protein Levels in Spinal Muscular Atrophy.
Ramirez A; Crisafulli SG; Rizzuti M; Bresolin N; Comi GP; Corti S; Nizzardo M
Int J Mol Sci; 2018 Jan; 19(1):. PubMed ID: 29316633
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
